Prospective, single-center, and exploratory study of temozolomide and rituximab for relapsed/refractory central nervous system lymphoma.
Not Applicable
- Conditions
- Relapsed/refractory central nervous system lymphoma
- Registration Number
- JPRN-UMIN000012730
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. Presence of uncontrollable infection. 2. Positive for serum anti-HIV antibody. 3. Positive for serum anti-HBV antigen or elevated serum HBV-DNA level.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall response rate and complete response rate.
- Secondary Outcome Measures
Name Time Method Overall survival, and progression-free survival.